These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 31057298)

  • 1. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
    Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP
    World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer.
    Guo GF; Jiang WQ; Zhang B; Cai YC; Xu RH; Chen XX; Wang F; Xia LP
    World J Gastroenterol; 2011 Nov; 17(43):4779-86. PubMed ID: 22147978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status.
    Schmitz KJ; Ademi C; Bertram S; Schmid KW; Baba HA
    World J Surg Oncol; 2016 Jul; 14(1):189. PubMed ID: 27444698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
    Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
    Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour location and efficacy of first-line EGFR inhibitors in
    Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E
    ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
    Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous activation of impaired autophagy and the mammalian target of rapamycin pathway in oral squamous cell carcinoma.
    Yin X; Hu L; Feng X; Wang H; Zhang C; Wang H; Wang S
    J Oral Pathol Med; 2019 Sep; 48(8):705-711. PubMed ID: 31132188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
    Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
    Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.
    Chen Y; Shi Y; Lin J; Ye YB; Wang XJ; Chen G; Guo ZQ
    Medicine (Baltimore); 2015 Oct; 94(40):e1698. PubMed ID: 26448020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy-related genes Raptor, Rictor, and Beclin1 expression and relationship with multidrug resistance in colorectal carcinoma.
    Shuhua W; Chenbo S; Yangyang L; Xiangqian G; Shuang H; Tangyue L; Dong T
    Hum Pathol; 2015 Nov; 46(11):1752-9. PubMed ID: 26363527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.
    Pichler M; Winter E; Stotz M; Eberhard K; Samonigg H; Lax S; Hoefler G
    Br J Cancer; 2012 May; 106(11):1826-32. PubMed ID: 22549179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer.
    Fiala O; Sorejs O; Hosek P; Liska V; Vycital O; Bruha J; Kucera R; Topolcan O; Finek J; Maceckova D; Pitule P
    Cancer Genomics Proteomics; 2020; 17(5):605-613. PubMed ID: 32859639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
    De Cuyper A; Van Den Eynde M; Machiels JP
    Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
    Hatch AJ; Sibley AB; Starr MD; Brady JC; Jiang C; Jia J; Bowers DL; Pang H; Owzar K; Niedzwiecki D; Innocenti F; Venook AP; Hurwitz HI; Nixon AB;
    Cancer Med; 2016 Sep; 5(9):2249-60. PubMed ID: 27465221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab.
    Campanella C; Mottolese M; Cianciulli A; Torsello A; Merola R; Sperduti I; Melucci E; Conti S; Diodoro MG; Zeuli M; Paoletti G; Cognetti F; Garufi C
    J Transl Med; 2010 Apr; 8():36. PubMed ID: 20398370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
    Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.